JP2017513476A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513476A5
JP2017513476A5 JP2016562499A JP2016562499A JP2017513476A5 JP 2017513476 A5 JP2017513476 A5 JP 2017513476A5 JP 2016562499 A JP2016562499 A JP 2016562499A JP 2016562499 A JP2016562499 A JP 2016562499A JP 2017513476 A5 JP2017513476 A5 JP 2017513476A5
Authority
JP
Japan
Prior art keywords
antigen
antibody variable
antigen binding
region
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016562499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513476A (ja
JP6635940B2 (ja
Filing date
Publication date
Priority claimed from EP14164523.4A external-priority patent/EP2930188A1/en
Application filed filed Critical
Publication of JP2017513476A publication Critical patent/JP2017513476A/ja
Publication of JP2017513476A5 publication Critical patent/JP2017513476A5/ja
Application granted granted Critical
Publication of JP6635940B2 publication Critical patent/JP6635940B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016562499A 2014-04-13 2015-04-12 三機能性抗原結合分子 Expired - Fee Related JP6635940B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14164523.4 2014-04-13
EP14164523.4A EP2930188A1 (en) 2014-04-13 2014-04-13 Trifunctional antigen-binding molecule
PCT/EP2015/057919 WO2015158636A1 (en) 2014-04-13 2015-04-12 Trifunctional antigen-binding molecule

Publications (3)

Publication Number Publication Date
JP2017513476A JP2017513476A (ja) 2017-06-01
JP2017513476A5 true JP2017513476A5 (https=) 2018-05-31
JP6635940B2 JP6635940B2 (ja) 2020-01-29

Family

ID=50478320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562499A Expired - Fee Related JP6635940B2 (ja) 2014-04-13 2015-04-12 三機能性抗原結合分子

Country Status (13)

Country Link
US (2) US20170037128A1 (https=)
EP (2) EP2930188A1 (https=)
JP (1) JP6635940B2 (https=)
KR (1) KR102392598B1 (https=)
CN (1) CN106661108A (https=)
AU (1) AU2015249006B2 (https=)
BR (1) BR112016023362A2 (https=)
CA (1) CA2945053A1 (https=)
DK (1) DK3131928T4 (https=)
MX (1) MX382970B (https=)
RU (1) RU2753882C2 (https=)
SI (1) SI3131928T2 (https=)
WO (1) WO2015158636A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
IL293435B1 (en) * 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7542438B2 (ja) * 2017-11-21 2024-08-30 ノバルティス アーゲー 腫瘍関連抗原に対する三重特異性結合分子及びその使用
EP3713959A1 (en) * 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
BR112020018492A2 (pt) * 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
PE20211916A1 (es) 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
HRP20240821T1 (hr) 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Cd19結合分子及びその使用
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16及びclec12aに結合するタンパク質
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
CR20230229A (es) * 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重car-t組成物及び方法
EP4284838A2 (en) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CN114044822B (zh) * 2021-10-28 2023-06-27 杭州博茵生物技术有限公司 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
ATE283925T1 (de) * 1996-07-23 2004-12-15 Tanox Pharma B V Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2003057829A2 (en) * 2001-12-26 2003-07-17 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from vh and vl domains
MXPA06004035A (es) * 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
JP5399712B2 (ja) * 2005-12-21 2014-01-29 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 可溶性ceaに対する抵抗性を有する医薬組成物
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
EP3581206B8 (en) * 2010-10-22 2025-02-19 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway

Similar Documents

Publication Publication Date Title
JP2017513476A5 (https=)
RU2016138347A (ru) Трифункциональная антигенсвязывающая молекула
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
PH12018501284A1 (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
JP2018537415A5 (https=)
JP2017504578A5 (https=)
CN111601825A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
MY207205A (en) Cd3 antibody and pharmaceutical use thereof
JP2014221064A5 (https=)
RU2011143905A (ru) ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab
JP2017176174A5 (https=)
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
AR106555A1 (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
RU2014109557A (ru) Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения
WO2012145507A3 (en) Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
MX356947B (es) Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
EA201790862A1 (ru) Связывающиеся с эритроцитами терапевтические средства
EA202190542A1 (ru) Сконструированные биспецифические белки
HK1207398A1 (en) Cd3 binding polypeptides
MX2013011176A (es) Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento.
RU2018102803A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2018522888A5 (https=)
MX2023012489A (es) Polipeptido de fusion biespecifico multifuncional.